hTf were used to seed collagen-coated nylon matrices, which were maintained in culture for up to 53 d. The rate of synthesis of hTf by the seeded matrices was constant after 22 d in vitro. Matrices seeded with cloned, transduced cells were implanted subcutaneously into seven athymic mice, and plasma levels of hTf were assessed biweekly. In all animals, the plasma level of hTf was detectable at week 6 after implantation. Levels of hTf remained elevated in the animals until the implants were removed at week 12. At week 10, the level ofhTfin the plasma correlated with tumor volume in tumors less than 2000 mm 3 in size. The half-life of hTf in the mice was 39.5 h. In this model, gene expression did not decline for the 12-week observation period. Key words: skin equivalents/ retrovirus/vectors. ] Invest Dermatol 104: [171] [172] [173] [174] [175] [176] 1995 clinical, developmental phase. Essential elements of gene therapy include identification, isolation, and expression of th e gen e of interest; efficient delivery of the gene into the target cells; and adequate and sustained expression of the gene produ ct in vivo. Many genes involved in inherited diseases have b een id entified to date, and it is expected that within the next 5-10 years most diseases with single-gene defects will be characterized on a molecwar level.
Recombinant retroviruses have been studied widely as a highly efficient system to integrate genes into the genome of the somatic cells. Recombinant retroviruses are produ ced by introducing the retroviral vector into a specialized packaging cell line, which produces replication-defective retroviruses encoding the gene of interest. These recombinant retroviruses have an amphotropic host range; i.e., they can infect a wide range of mammalian species [9] . Cellular proliferation is necessary for retroviral infectio n and integration (transduction), and the efficiency of transd uctio n of target cells has been reported to approach 100% in some systems [10] .
Ideally, integration of the recombinant vector into the h o st genome reswts in permanent expression of the intr oduced gene, alth ough sustained expression of these genes has b een difficwt to accomplish in animal models [11] [12] [13] .
Despite recent ad vances, many issu es rem ain to b e addressed before somatic gene therapy can be u sed m o re wid ely in the treatment of disease. M ethod s to maximize transgen e expression and delivery in vivo and the pharmacokinetics of th e transg ene 0022 
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product are specific issues addressed in this study, which examines a gene-therapy model system using a recombinant retrovirus encoding the gene for human transferrin (hTf). The target cells, NIH 3T3 fibroblasts, were modified genetically using the recombinant retrovirus, and clones of transduced cells producing high levels of hTf were isolated. A shuttle system consisting of a collagen-nylon matrix seeded with the transduced, cloned 3 T3 cells was implanted subcutaneously into athymic mice, plasma levels of hTf were measured, and the pharmacokinetics of hTf in the mouse were determined.
MATERIALS AND METHODS
Retroviral Vector and Packaging Cell Line A recombinant retrovirus derived from the Moloney murine leukemia virus was made to encode hTf using a cDNA from hTf obtained from Dr. R. MacGillivray (University of British Columbia, Vancouver, Canada). To accomplish this , a two-step procedure was used to remove the 5' and 3' noncoding regions of the transferrin cDNA. A fragment from the 3' end of transferrin (Pstl to Acel) was isolated and inserted into a pGEM cloning vector digested with Pstl and BamHl. The fragment was inserted along with two complementary synthetic oligonucleotides (5' agccttaaagatct 3' and 5' gatcagatctttaaggt 3'), which when annealed have ends compatible with Acel and BamHl sites and also create a synthetic Bgi II site just after the translational stop codon. This 3 ' fragment was isolated from the subclone (Pstl to Bgi II) and inserted into the Ncol/BamHl site of the MFG retroviral vector [3] as part of a four-part ligation, which included a fragment from the 5' end of the transferrin cDNA (Ban2 to Pstl) and two complementary synthetic oligonucleotides. These oligonucleotides (5' catgaggctcgccgtgggagcc 3 ' and 5 ' cccacggcgagcct 3') anneal to form a synthetic fragment that has ends compatible with Ncol and Ban2 sites. The translational start codon (atg) of the Ncol site corresponds to the translational start codon of the transferrin open reading frame: thus , the 5' non-coding sequences are removed from the cDNA. The assembled vector was verified by restriction enzyme analysis, and the 5' and 3' ends of the gene were verified by DNA sequencing (Fig 1) .
This retroviral vector (MFG-hTf) was introduced into the 'l'CRlP packaging cell line by co-transfection with pSV2 His, a plasmid that confers resistance to histidinol [14, 15] . Two days after transfection, the cells were split into selective media (medium minus histidine with 1 mM histidinol) . Histidinol-resistant clones were isolated, expanded, and screened for the production of retrovirus encoding hTf.
The packaging cell line was cultured in Dulbecco' s modification of Eagle's medium (DME) (Sigma, St. Louis, MO) with 10% bovine calf serum (Gibco , Grand Island, NY). Virus-containing medium was harvested from each of the clones after they reached confluence in a 24-well dish; 8 J-Lg/ml polybrene (Sigma) was added, and the medium was used to infect another 24-well dish into which 1 X 10 4 3T3 cells had been plated the previous day. The cells were refed after 48 h, and the conditioned medium containing transferrin secreted by the infected 3T3 cells was collected 24 h later and frozen. The level of hTf in the conditioned medium was measured by enzyme-linked irnmunosorbent assay (ELISA) (see below). The clone of the packaging cell line producing the highest level of recombinant virus was identified by the highest level of transferrin production in the media of the infected 3T3 cells. This clone (designated T38) was expanded further and used as the packaging cell line for the experiments described below.
Transduction of 3T3 Fibroblasts Nonconfluent cultures of 3T3 fibroblasts, grown in DME with 10% bovine serum, were incubated at 37°C in undiluted T38-conditioned medium containing 8 J-Lg/ml polybrene. Mter overnight incubation, the cells were incubated in fresh T38-conditioned medium with 8 J-Lg/ml polybrene for 2 h. Following this incubation, the cells were grown to confluence in DME with 10% calf serum. Upon THE JOURNAL OF INVESTIGATIVE DERMATOLOGY confluence the medium was changed, and after 24 h the medium was assayed for hTf with ELISA.
Clonal Expansion ofhTf-3T3 Fibroblasts Cultures of transduced 3T3 cells producing high levels of hTf (designated hTf-3T3) were cloned by limiting dilution into 24-well plates. Eight clones expressing high levels o j hTf were expanded in 60-mm culture dishes. The two clones producing tht highest levels of hTf were used to seed the dermal matrices.
Preparation ofhTf-3T3/Collagen Matrices Nylon mesh matrices. 1. 2 cm 2 , were obtained from Advanced Tissue Science (La Jolla, CA). Thes matrices are seeded and "conditioned" with 25 X 10 6 human neonatal dermal fibroblasts by the manufacturer. After 2-3 weeks, the neonatal fibroblasts were lysed hypotonically as follows: the matrix was rinsed with sterile water, covered with sterile water, and stored overnight at -70°C , thawed, and rinsed twice with sterile water. The "conditioned" matrices. containing no viable cells, were shipped frozen in DME. Matrices were stored at -20°C before seeding with cloned hTf-3T3 fibroblasts. For seeding, the matrices were placed in six-well tissue culture plates and thawed. Cloned hTf-3T3 cells were dissociated with 0.025% trypsinethylenediamine tetraacetic acid, and 1 X 10 6 cells in 50 J-LI DME with 10% bovine calf serum were pipetted onto the top of each matrix. The matrices then were incubated at 37°C to allow the cells to migrate into the matrix. After 3 h, 4 ml ofDME with 10% bovine serum was added to each well. and the plates were incubated overnight at 37°C. The next day, the medium was removed and a second 50-J-LI aliquot of 1 X 10 6 cells was added to each matrix for 3 h, after which the matrices were refed with 4 ml of DME with 10% bovine calf serum. These hTf-3T3/ collagen matrices were maintained in culture for 11-53 d in DME with 10% bovine calf serum at 37°C. Conditioned medium was collected every third day from these cultures and assayed for hTf.
Implantation of 3T3/Collagen Matrices Two 3T3/ collagen matrices, which had been maintained in culture for 53 d , were bisected and implanted subcutaneously in both thoracic flanks of two athymic (Balb/c nu/nu) adult mice (Charles River Laboratories, Wilmington, MA). Similarly, matrices maintained for 11 d in culture were implanted unilaterally into five mice. Two mice were implanted with matrices that had not been seeded with cells, and one animal was implanted with a matrix seeded with 3T3 cells transduced with a retrovirus encoding J3-galactosidase. Matrices were attached to the overlying skin with a surgical staple. After 1 week, the staples were removed and the matrices remained fixed in the subcutaneous space.
Matrices seeded with non-transduced 3T3 fibroblasts form tumors when implanted in athymic mice [16] . The animals were inspected weekly for tumor growth, and tumor volume was estimated from calipers measurements of the tumors in situ at week 10 and upon removal of the tumors at week 12.
hTf Levels in Grafted Mice Experimental animals were bled from the tail vein before implantation of the 3T3/ collagen matrices and at biweekly intervals post-transplantation. The blood was centrifuged and the serum assayed for hTf with ELISA.
ELISA for hTf The concentration ofhTfin the conditioned medium and the plasma of the mice was measured with a standard competition ELISA. Wells of flat-bottom microtiter plates were incubated overnight with purified human apotransferrin (0.4 J-Lg/well, Sigma) in Voller's buffer. Duplicate samples of human apotransferrin, 0.1 J-Lg/I00 J-LI, and the samples were added to round-bottom micro titer plates and dilu ted serially. Goat anti-hTfantibody (100 J-LlIwell, Organon Teknika Corp. , Westchester, PA) was added to each well for a final dilution of 1: 1 0,000, and the plates were incubated overnight at 4°C. The contents of the round-bottom wells were transferred to the antigen-coated plates and incubated for 2 h at 25°C. These plates were then washed, and 200 J-LI of rabbit anti-goat IgG (1:1000, Organon Teknika) was added to each well for 90 min at 25°C. Phenylenediamine dihydrochloride was used as the substrate solution, and absorbance was measured at 490 nm . The lower limit of detection of this assay was estimated as 0.5 J-Lg/ ml. Southern Blot Hybridization DNA was extracted from the cells using standard techniques [17] . DNA digests were prepared using the restriction endonuclease PST 1 (Boehringer Mannheim Corp., Indianapolis, IN) . Digests were run on an agarose gel, transferred to S&S Nytran Plus membranes (Schleicher & Schuell, Inc., Keene, NH), hybridized with 32P-Iabeled hTf eDNA, washed, and reprobed with a radiolabeled control cDNA, v-fos (Clontech Laboratories, Inc., Palo Alto, CA), which yields a single band in mouse DNA digested with PST 1. Autoradiograms were analyzed using a Bio-Rad GS-250 Molecular Imager, and a ratio of the hTf signallv-fos signal for each sample was calculated. number of wells Figure 2 . Levels of hTf produced by cloned hTf-3T3 fibroblasts. 3T3 fibroblasts were transduced with a retroviral vector encoding the gene for hTf. After transduction, the cells were cloned by limiting dilution into 24-well plates. Wells displaying evidence of clonal growth were grown to confluence, and hTflevels in the conditioned medium were measured with ELISA. The distribution of these levels is shown. The number at the end of each bar is the number of clones producing hTf within the range specified. A majority (53%) of the clones produced hTf above the detection limit of 0.5 /-Lg/ml. Eight clones producing high levels ofhTf (0.9-1.3 /-Lg/ml) were expanded in culture. 34 JLg/ml) were expanded into 60-mm culture dishes. Two of the expanded clones (BTl-4C, BT4-3B) were found to produce especially high levels of hTf (5.53 and 4.99 J.Lg/ml, respectively) and were used to seed the collagen matrices. No hTfwas detected in the supernatants from non-transduced 3T3 cells or in supernatants from cultured human neonatal and adult fibroblasts (data not shown). The wide range of hTf produced by the cloned cells was intriguing. We hypothesized that the clones producing high levels of hTf had multiple copies of the hTf gene integrated into their genome. To test this, we performed Southern blot hybridization on DNA extracted from a high-producing and a lower-producing 3T3 clone; from transduced, non-cloned 3T3 cells; and from unmodified 3T3 cells (Fig 3) . The signals from these samples were compared with the signals generated using 3T3 DNA "spiked" with known quantities of the cDNA corresponding to the hTf gene. The intensity of the hTf signals from both clones (lanes 6 and 7) , the non-cloned transduced 3T3 cells (lane 8) , and the 3T3 "spiked" with 10 pg of hTf cDNA (lane 3) were approximately equal. This amount ofhTf cDNA, 10 pg, is equivalent to two copies of the hTf gene per cell. Therefore, because the two 3T3 clones had integrated the same number of copies of the hTf gene (n = 2), the difference in transferrin production was not due to the presence of a greater number of gene copies. Thus, we hypothesize that the hTf retrovirus may have integrated into more transcriptionally active and stable sites in the clones producing higher levels of hTf, resulting in higher gene expression in these cells.
hTf-3T3/Collagen Matrices Produce hTf for 53 d In Vitro As stated previously, collagen matrices were seeded with cells derived from the BTl-4C and BT4-3B clones. The seeded matrices were maintained in culture for 53 d, and the rates of hTf produced by these matrices were measured (Fig 4) . Mter seeding, the rate of hTf synthesis increased initially during the first 3 weeks in culture, then remained relatively constant from day 22 to the end of the experiment at day 53. Appreciable concentrations of hTf (0.3 J.Lg/ml) were measured per 24-h period in both matrices.
Because the concentration ofhTfin the medium reflects the rate of synthesis less the rate of degradation, the degradation rate ofhTf in the medium was determined. Radiolabeled hTf C 2s I-hTf) was added to the medium of cultured hTf-3T3/collagen matrices. Mter 30 h, the amount of trichloroacetic-acid-soluble radioactivity in the conditioned medium was measured. No radioactivity was detected in the trichloroacetic-acid-soluble fraction over this period; therefore, the 12sI_hTf was metabolically stable and not degraded under these culture conditions. Thus, the concentration of hTf in the medium of the cultured hTf-3T3/collagen matrices accurately reflected the rate of synthesis.
We found the rate ofhTf synthesis in culture to be reproducible in a second group of five matrices seeded with cells of the BTl-4C clone. Media from these seeded matrices were collected at day 11 in vitro, pooled, and assayed for hTf. The rate of synthesis ofhTfin these cultures was 0.33 J.Lg/m1l24 h on day 11. This rate was comparable to the synthesis rate on day 11 measured in the initial set of two matrices (0.2 J.Lg/m1l24 h), as shown in Fig 4. Because it was not possible to measure accurately the number of cells populating the matrix, the rate of production per cell could not be A. c. detennined. However, morphologic observations suggest that the number of cells in the matrix does not increase appreciably after 3-4 weeks in culture. Thus, we conclude that the transduced, cloned cells maintained their rate of production of the gene product for an extended period in culture.
hTf Was Detected in the Plasma of Athymic Mice Implanted With hTf-3T3/Collagen Matrices After 53 d in vitro,
hTf-producing matrices were implanted subcutaneously into two athymic mice. Plasma levels of hTf in the mice were assayed at biweekly intervals. In no instance was hTf detected in the plasma of mice implanted with non-seeded matrices or in the mouse implanted with a matrix seeded with 3T3 cells transduced with a retrovirus encoding {3-galactosidase. Low levels of hTf were measured at 2-6 weeks in the two experimental mice (Fig 5) . Subsequently, increasing amounts of hTf were detected at 8-12 weeks, such that the concentration of time (wk) Figure 5 . Plasma levels of hTf in two mice implanted with matrices maintained in culture for 53 d. Two matrices seeded with cloned hTf-3T3 cells (BT1-4C, circles; BT4-3B, diamonds) that had been maintained in culture for 53 d (Fig 4) were implanted subcutaneously into two athymic mice. Plasma hTf levels were assessed biweekly after implantation. The plasma level of hTf was low for 6 weeks, then increased until the matrices were removed at week 12. The increase in hTf paralleled the development of tumors at the site of implantation (see Results). The concentration ofhTf at week 12 equaled 30 fLg/ml (4.0 X 10-7 M), a level comparable to that seen in human plasma. After removal of the matrices, plasma hTffell rapidly and was essentially nondetectable within 4 d. Figure 6 . Plasma levels ofhTfin five mice implanted with matrices maintained in culture for 11 d. Five mice were implanted with matrices seeded with the BTl-4C clone of transduced cells 11 d before implantation. As in the first two animals (Fig 5) , plasma levels ofhTf remained low for the first 6 weeks post-implantation. The level of hTf increased between weeks 6-8 in all animals and appeared to plateau after week 8 in three of the five animals. Levels of hTf were comparable to those seen in the animals implanted with the 53-d matrices (Fig 5) . Matrices seeded with cloned hTf-3T3 cells and maintained in culture for 11 d were implanted into five additional mice. In these animals, little plasma hTf was detected before week 8 (Fig 6) , an observation consistent with the results from the experiment using two mice implanted with the 53-d matrices. After week 8, all animals showed measurable levels of hTf. There was variation in terms of the absolute levels of hTf measured in individual animals and the times at which a given level was observed. However, all seven mice implanted with hTf-expressing matrices demonstrated similar peak levels of hTf (Figs 5, 6 ).
In these experiments, athymic mice implanted with matrices seeded with 3 T3 fibroblasts developed tumors at the site of the implants, possibly due to genetic instability of the 3T3 cells and the abnormal immune system of the athymic mice. Tumor development was not dependent on transduction of the 3T3 cells, as matrices seeded with cloned, non-transduced 3T3 cells also produced tumors (G.G. Krueger, unpublished observation, 1994) . At week 12, tumors were removed from the mice implanted with hTf-producing matrices, and the half-life (t l 12 ) of hTf in vivo was determined by measuring plasma hTf at 24, 48, and 96 h after tumor removal in three animals. The average tll2 was 39.5 h (Fig  7) , as calculated from the slope of the exponential curve of the disappearance ofhTf from plasma (t1l2 = In 2/slope). The half-life of hTf measured in the grafted mice was very similar to that in normal and hypotransferrinemic mice after intraperitoneal injection ofhTf (tll2 = 33 h; J. Kaplan, unpublished observation, 1991).
Plasma hTfLevels Correlclte With Tumor Size The relation between plasma level of hTf and tumor volume was analyzed at week 10 (Fig 8) . In animals with tumors less than 2000 mm 3 Figure 7 . The half-life of hTf in three mice after removal of the implants was 39.5 h. A) Plasma levels of hTf were measured 24 48 and 96 h after removal of the implants in three animals. The half-life ~f hTf in each animal was calculated (t1l2 = In 2IB; B = slope of exponential curve).
B) The average of the three curves in A is shown. The average half-life of hTf was 39.5 h.
within t~e larger tumors. Thus, beyond a certain volume, larger tumor SIze does not reflect an increased number of cells. These observations suggest that hTf production was dependent on cell number as opposed to tumor volume.
DISCUSSION
Genetic modification and transplantation of skin cells has been proposed as a means of supplying deficient plasma proteins, as well as other cellular products such as cytokines [12, 13, 18] . Key factors to t~s approach include isolation and culture of the target cells, effiCIent transduction of the genetic material of interest, transplantation of the genetically modified cells into the host, and long-term expression of the introduced gene product in the host. This study explored these factors in detail.
A retroviral vector containing the gene for hTfwas used in these experiments. The hTf gene was selected in conjunction with ongoing research efforts of one of the authors OK) examining iron metabolism and hemochromatosis using a hypotransferrinemic mouse model [19] . total number of clones expressing hTf at 0.5 J.Lg/ml (the lower limit of detection in the assay) or greater. Although this represents an acceptable transduction efficiency, we chose to clone the transduced cells to seed the matrices exclusively with cells expressing hTf, thereby maximizing production in vivo.
Mter the dermal matrices were seeded with a clonal population of transduced 3T3 cells, the rate of hTf production in vitro was relatively constant after 22 d. This suggests that the matrices were populat~d with a maximum number of transferrin-producing fibroblasts after 3 or more weeks in culture. More important, as demonstrated in the matrices maintained in culture for 53 d, there was no decline in hTf levels over time; this suggests that gene expression was not significantly down-regulated or inactivated for up to 8 weeks in vitro.
Other investigators have used implants of genetically modified fibroblasts within a collagen matrix as a means of administering a "new" gene product [6, 12, 13, 18] . The development of tumors by the matrices after implantation increased the number of genetically modified cells per animal as a function of time, and high levels of hTf (30 J.Lg/ml, 4.0 X 10-7 M) were achieved in the plasma of the implanted mice as the tumors enlarged. Although the concentration of hTf in human plasma is much higher (3 X 10-5 M), the concentration of hTf in the implanted mice exceeds that required for hematopoeisis in humans (1 X 10 -8 M). The plasma concentration of hTf correlated closely with tumor size until the tumors became cystic as they enlarged. Correlation of plasma levels of the gene product with tumor size or cell number is an important element of an effective gene-therapy system, as it suggests that blood levels can be augmented by increasing the number of genetically modified cells introduced into the recipient. Finally, the disappearance of hTf from the plasma of the mice after tumor removal suggests that these genetically modified cells did not metastasize to distant sites, another important element of an effective gene-therapy system.
Expression of hTf persisted for up to 84 d in vivo in mice implanted with matrices maintained in culture for either 11 or 53 d. Thus, these transduced cells continued to express the hTf gene for over 130 d. Moullier et al [20] reported sustained expression of a transduced gene, f3-glucuronidase, for 155 d from genetically modified fibroblasts in a collagen lattice implanted intraperitoneally, as assessed by the level of enzyme activity in tissue. However, persistence of a transduced gene product in the plasma of transplanted animals has been more difficult to achieve [21] . Several mechanisms have been implicated in the disappearance of these proteins from plasma: 1) development of antibodies to the foreign ~rot~in, .2) rapid clearance of the protein from plasma, and 3) mactlvatIOn or down-regulation of the vector in vivo. The persistence of plasma hTf in mice implanted with matrices containing cloned hTf-3T3 cells suggests that such mechanisms were not operative in our system. The absence of T cells in athymic mice precludes development of antibodies directed against foreign prote~s, as desc?bed in immunologically competent mice implanted With syngeneIC cells transduced with the gene for human factor IX [11] . The concentration ofhTf and its long half-life (39.5 h) in the implanted animals suggest that hTf was not cleared rapidly from the plasma in these mice. In contrast, human factor VIII was cleared ~apidly fro~ the plasma of athymic animals implanted with genetcally modIfied fibroblasts [13] , presumably related to properties inh~re~t to fa~tor VIII that facilitate its clearance from the plasma.
. S~ilarly, different factors are believed to mediate vector expresSIOn m transduced cells. As such, the integration site of the vector into the genomic DNA of the transduced cells may affect vector expression. In our study, Southern blot analysis demonstrated that ~tegration of additional gene copies was not responsible for the high levels ofhTf detected in the high-producing clones relative to the 10': producers. Therefore, we hypothesized that the highproducmg clones represented cells in which the viral vector had integrated into transcriptionally stable and active sites, leading to sustained expression of the trans gene product. In contrast, loss of gene expression, resulting from down-regulation of vector expres-sion, occurs over time. Down-regulation of gene expression was postulated to explain the disappearance of human adenosine deaminase from dermal equivalent grafts containing rat fibroblasts transduced with the human adenosine deaminase gene, as vector sequences were detected for months in the grafts after human adenosine deaminase levels had fallen [12] . The promoter that drives transcription of the introduced gene also may be a key factor in determining long-term expression in vivo. Scharfmann et al [21] demonstrated prolonged expression (60 d) of a /3-galactosidase gene linked to a housekeeping gene promoter, dihydrofolate reductase, compared with that linked to a cytomegalovirus promoter. In the recombinant retrovirus used in our study, the 5' long-terminal-repeat promoter directs transcription of the hTf gene. Whereas bone marrow cells transduced with retroviral transcripts encoding the human adenosine deaminase gene linked to the long-terminal-repeat promoter have expressed this gene in vivo for up to 5.5 months [22] , expression of long-terminal-repeatdriven genes in fibroblasts for longer than 2 months in vivo has not been reported [21, 23] .
In conclusion, we have analyzed a model system of gene therapy to correct deficiencies of plasma proteins. Important features demonstrated with this model include selection of a clone of cells producing high levels of the introduced gene product, expansion of this clone for use in the transplanted dermal matrices, consistent gene expression for over 18 weeks (130 d), and correlation of plasma levels with the size of the developing tumors containing the genetically modified cells. These findings support the hypothesis that autologous fibroblasts with a stable transgene that is transcriptionally active are a reasonable target for genetic modification to correct deficiencies in plasma proteins. It also seems likely that such a system could be used to correct localized inherited diseases of the skin, with a trans gene product being delivered in a paracrine fashion. 
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